Acarbose is an old, inexpensive type 2 diabetes drug that works in the gut: it slows the enzymes that break starch into sugar, so less glucose enters the blood after a meal and the post-meal spike is smaller. In type 2 diabetes it lowers HbA1c modestly, and in the STOP-NIDDM trial it reduced the rate at which people with prediabetes progressed to diabetes. Its cardiovascular record is more mixed: STOP-NIDDM reported a heart-event benefit from a small number of events, and the larger ACE trial, built specifically to test that, found no reduction in heart events while confirming the diabetes-prevention effect.
Acarbose entered the longevity conversation through animal work: in the National Institute on Aging Interventions Testing Program it extended lifespan in genetically diverse mice, far more in males than females, a result that was replicated. There is no human longevity trial, the carbohydrate fermentation that may drive the mouse effect is also what causes the gas and bloating that make acarbose hard to tolerate, and this is a clinician-prescribed drug. The basics come first, and this page gives no dose.
Findings & Outcomes
What It Is
Acarbose is an oral type 2 diabetes drug in use since the 1990s. It belongs to a small class called alpha-glucosidase inhibitors, which act inside the small intestine and are barely absorbed into the body, so most of its effect and most of its side effects stay in the gut. For much of its history it was a second-line drug, used when the main problem was high blood sugar after meals, and it is common in parts of East Asia where diets are high in starch. It is inexpensive and off-patent.
Aging research then examined acarbose for a different reason. In a program that tests drugs for lifespan in genetically diverse mice, acarbose made the animals live longer, and it did so far more in males than in females, a pattern that has held up on repetition. That result, together with the way the drug changes what happens to carbohydrate in the gut, is why acarbose now appears on lists of candidate longevity drugs.
What It Does
Acarbose does three separable things, and each rests on a different strength of evidence. Reading them from the settled to the speculative keeps the drug in proportion.
The metabolic effects are the settled part, from randomized trials. In type 2 diabetes acarbose lowers HbA1c by around 0.8 percentage points, a modest drop that comes almost entirely from flattening the post-meal rise, and it is weaker than metformin at usual doses. In prediabetes, the STOP-NIDDM trial found it cut progression to type 2 diabetes by about a quarter over roughly three years, and the larger ACE trial later confirmed a diabetes-prevention effect of similar size. This is where the evidence for acarbose is strongest, and it suits people whose main problem is the after-meal spike.
The cardiovascular claim is the contested part, and it is often stated more firmly than the evidence allows. STOP-NIDDM reported a striking drop in cardiovascular events, but that rested on a small number of events in a secondary analysis and drew heavy criticism. The ACE trial was built specifically to settle the question, in more than six thousand people with coronary heart disease and prediabetes, and it found no reduction in cardiovascular events. When a small secondary finding and a trial designed to test it disagree, the dedicated trial is the one to weigh, so the fair reading is that acarbose lowers blood sugar and delays diabetes while its effect on the heart is unsettled.
The longevity claim is the speculative part, and it is entirely in mice. In the National Institute on Aging Interventions Testing Program, which runs the same test across three independent laboratories to weed out flukes, acarbose extended median lifespan by about 22% in males and about 5% in females, and a higher-dose study repeated the male-biased pattern. That sex difference is not explained. The same colonic fermentation that may drive the mouse effect is what produces the gas and bloating that make the drug hard to tolerate.
No completed human study shows acarbose extends healthy lifespan or healthspan, and there is no established dose for that use.
The Research & Studies
Everything here is based on the research we have collected and checked, sorted into groups and ordered with the strongest evidence first. Click any claim to open the studies behind it.
Blood Sugar
Lowers HbA1c about 0.8 percentage points in type 2 diabetes
Acarbose lowers long-term blood sugar in type 2 diabetes by a bit under one percentage point of HbA1c, a modest drop.
In a Cochrane review of alpha-glucosidase inhibitors in type 2 diabetes, acarbose lowered HbA1c by about 0.8 percentage points versus placebo, a smaller reduction than metformin typically produces, acting mainly by blunting the post-meal glucose rise. Measured in: Pooled randomized trials of acarbose and other alpha-glucosidase inhibitors in adults with type 2 diabetes.. The pooled trials varied in dose, duration and diet, and many were short; the glycemic effect is smaller than that of first-line drugs.
The study · 1
Van de Laar et al., alpha-glucosidase inhibitors for type 2 diabetes mellitus (Cochrane review) · Cochrane Database Syst Rev 2005
Cut progression from prediabetes to diabetes about 25% over 3.3 years (STOP-NIDDM)
In people with prediabetes, acarbose cut the rate of developing type 2 diabetes by about a quarter over roughly three years.
In the STOP-NIDDM trial, acarbose reduced the relative risk of progressing from impaired glucose tolerance to type 2 diabetes by about 25% (hazard ratio 0.75) over a mean 3.3 years versus placebo. Measured in: 1,429 adults with impaired glucose tolerance, randomized to acarbose or placebo, mean follow-up 3.3 years.. A high dropout rate, largely from gastrointestinal side effects, complicated the analysis, and some diabetes diagnoses appeared soon after acarbose was stopped.
The study · 1
Chiasson et al., acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial · Lancet 2002
The same ACE trial cut new diabetes about 18%
The same large trial that found no heart benefit did confirm that acarbose reduced the onset of diabetes.
In the same ACE trial, acarbose reduced the incidence of new type 2 diabetes by about 18% (rate ratio 0.82) versus placebo, confirming a diabetes-prevention effect of similar size to STOP-NIDDM. Measured in: 6,522 Chinese adults with coronary heart disease and impaired glucose tolerance, median follow-up 5 years.. The absolute reduction was modest and this population already had coronary disease, so the prevention benefit should be read alongside the drug tolerability.
The study · 1
Holman et al., effects of acarbose on cardiovascular and diabetes outcomes in patients with coronary heart disease and impaired glucose tolerance (ACE) · Lancet Diabetes Endocrinol 2017
Counts once: this finding and 1 other here come from the same source, so they are one body of evidence, not separate confirmations.
Heart And Vascular
No reduction in cardiovascular events in the larger ACE trial (hazard ratio 0.98)
In a large trial built to test it, acarbose did not lower the rate of heart attacks, strokes or cardiovascular death.
In the ACE trial, acarbose did not reduce the primary composite of major cardiovascular events (hazard ratio 0.98) in Chinese adults with coronary heart disease and impaired glucose tolerance over a median 5 years. Measured in: 6,522 Chinese adults with coronary heart disease and impaired glucose tolerance, randomized to acarbose or placebo, median 5 years.. The trial was in an East Asian population with established coronary disease, so it does not rule out a different effect in other groups, but it directly contradicts the earlier cardiovascular signal.
The study · 1
Holman et al., effects of acarbose on cardiovascular and diabetes outcomes in patients with coronary heart disease and impaired glucose tolerance (ACE) · Lancet Diabetes Endocrinol 2017
Counts once: this finding and 1 other here come from the same source, so they are one body of evidence, not separate confirmations.
STOP-NIDDM hinted at 49% fewer cardiovascular events, from very few events
An early trial hinted acarbose might reduce heart events in prediabetes, but the signal came from very few events and was not convincing on its own.
A secondary analysis of STOP-NIDDM reported that acarbose was associated with a 49% relative reduction in cardiovascular events and fewer myocardial infarctions, but the finding rested on a small number of events and was widely criticized. Measured in: 1,429 adults with impaired glucose tolerance in STOP-NIDDM; cardiovascular events were a secondary endpoint with few total events.. The cardiovascular result was a secondary endpoint based on a handful of events (for example one versus twelve myocardial infarctions), and a later dedicated trial did not confirm it.
The study · 1
Longevity And Mortality
Extended median lifespan about 22% in male mice, about 5% in females
Acarbose made mice live longer, with a much bigger effect in males than females, in a careful multi-laboratory study.
In the NIA Interventions Testing Program, acarbose added to the diet from 4 months of age (young adulthood) extended median lifespan by about 22% in male genetically diverse mice and about 5% in females, a sex-biased effect seen across three independent laboratories. This is an animal result in mice, and the strong sex difference is unexplained; it cannot be read straight across to people.
The study · 1
Harrison et al., acarbose, 17-alpha-estradiol, and nordihydroguaiaretic acid extend mouse lifespan preferentially in males · Aging Cell 2014
Higher doses raised male mouse lifespan 16% or 17%, females 4% or 5%
A second mouse study at higher doses again extended male lifespan more than female, by about 16% or 17% in males, and it still worked when treatment began later in life.
A follow-up Interventions Testing Program study tested acarbose at three doses and found the two higher doses raised male mouse median lifespan by 16% or 17% and female median lifespan by 4% or 5%, replicating the male-biased benefit even when treatment began later in life. This remains a mouse result; the replicated sex difference and the reliance on continuous dietary dosing limit how far it can be carried to humans.
The study · 1
Harrison et al., acarbose improves health and lifespan in aging HET3 mice · Aging Cell 2019
How it works
Gut fermentation and short-chain fatty acids: a proposed mouse longevity mechanism
In mice, acarbose changed the gut bacteria and increased helpful fermentation products, and those changes lined up with how much longer the mice lived.
In mice, acarbose shifted the composition of the gut microbiome and raised levels of short-chain fatty acids such as butyrate and propionate, and the degree of these changes tracked with the lifespan extension, suggesting colonic fermentation is part of the mechanism. This is a correlation within mouse studies between microbiome changes and lifespan, not proof that the short-chain fatty acids cause the longevity effect.
The study · 1
Smith et al., changes in the gut microbiome and fermentation products concurrent with enhanced longevity in acarbose-treated mice · BMC Microbiol 2019
Anatomy
1A gut-acting drug
Acarbose is an alpha-glucosidase inhibitor, given by mouth with the first bite of a meal. Unlike most diabetes drugs it is hardly absorbed into the body. It does its work in the small intestine, which is also why its side effects are digestive. It reached wide clinical use in the 1990s and is inexpensive and off-patent.
2How it blunts the sugar spike
Enzymes in the intestinal wall normally break starch and sucrose into glucose so it can be absorbed. Acarbose slows those enzymes, so carbohydrate is digested more gradually and glucose enters the blood more slowly. The result is a lower and flatter rise in blood sugar after a meal, which is where the drug does most of its glycemic good.
3The carbohydrate that reaches the colon
Because some carbohydrate is not broken down in the small intestine, more of it passes into the colon, where gut bacteria ferment it. That fermentation produces short-chain fatty acids such as butyrate, and it also produces the gas that is its main side effect. The same fermentation is one of the mechanisms researchers suspect in the animal longevity findings.
How to Approach It
This is education, not a protocol, and there are no doses or product links here. Acarbose is a prescription drug, so whether it fits is a decision made with a clinician. This section covers where the diabetes evidence is solid, where the cardiovascular claim did not hold, and what a mouse lifespan result means for a person considering the drug.
Acarbose flattens the blood-sugar rise after a starchy meal, and so does eating fewer refined carbohydrates, walking after meals, and building muscle that takes up glucose. These foundations carry far stronger evidence for metabolic health and healthy aging than any longevity drug. See [resistance training](/go/integrative/practice/resistance-training) for holding muscle with age.
For type 2 diabetes acarbose lowers HbA1c modestly, and for prediabetes it reduced progression to diabetes in two randomized trials. It suits people whose main problem is the after-meal spike, and it is inexpensive. Whether it fits your blood sugar, your other medicines and your tolerance for its gut effects is a conversation with a prescriber, who sets the dose.
The heart-protection idea comes from STOP-NIDDM, whose cardiovascular result rested on a handful of events. The larger ACE trial, built to test it, found no reduction in heart events. If cardiovascular benefit is the reason acarbose is being considered, that later trial is the one to weigh.
The lifespan extension is replicated and larger in males, and it is entirely in mice. There is no human longevity trial and no established dose for that use. The sober step is to follow the research and weigh it with a clinician; an animal finding is not a reason to start, especially given how the drug is tolerated.
Go Deeper
- The biology of aging: where nutrient handling and the gut sit among the hallmarks of aging, and how to read an animal drug result against the human evidence.
- Insulin and glucose handling: the metabolic system acarbose acts on, and why flattening the after-meal glucose rise matters.
- Metformin: the other cheap diabetes drug at the center of the longevity question, with a stronger glycemic record and the same gap between hint and proof.
- Berberine: the plant compound often sold as a natural blood-sugar agent, and what its evidence shows.
The Chinese Medicine View
Acarbose is a product of modern pharmacology, developed in the twentieth century, so there is no classical Chinese entry for it. No historical text assigns it a channel, a temperature or a flavor, and no traditional formula contains it. This places the drug against the tradition as a lens, not as evidence, and no classical claim applies, because none exists. Nothing here suggests any herb or formula reproduces what acarbose does.
The territory the drug acts on is one the tradition has long reasoned about. The Spleen and Stomach, in this framework, govern the transformation and transport of food into usable substance. When that work is overwhelmed by rich or excessive eating, the tradition describes food stagnating and turning to Dampness and Phlegm, patterns often mapped onto the modern picture of insulin resistance and excess weight. A drug that slows the breakdown of a heavy starchy meal is, in a loose sense, acting within the same domain the tradition assigns to digestion.
The tradition cautions in two opposite ways here. Its counsel toward moderation in eating, the idea in Yang Sheng of not overwhelming the digestion, aligns with a drug whose purpose is to soften the effect of a large carbohydrate load. But the same framework holds that the Spleen dislikes Dampness and stagnation, and a drug that leaves undigested carbohydrate to ferment and generate gas is, in these terms, producing the very stagnation and fullness the tradition treats. That is a fair way to understand why bloating is its common complaint.
The limit here is that this is a way of relating a modern drug to a framework the tradition has long reasoned about, not a claim that Chinese medicine endorses or explains acarbose. The evidence for the drug rests on its own trials, of which the diabetes record is moderate, the cardiovascular record is negative in the trial built to test it, and the longevity record is entirely in animals.
Cautions
Everything to be aware of is here, in one place. This practice suits most healthy people; a few situations call for real care.
Gas, bloating and diarrhea are the main reason people stop acarbose
Across the trials pooled in the Cochrane review, acarbose caused substantially more flatulence, bloating and diarrhea than placebo, and these gastrointestinal effects were the main reason participants stopped the drug. The side effects are dose-related and often ease with a slow increase, but they drive high discontinuation rates and complicated the trials.Van de Laar et al., alpha-glucosidase inhibitors for type 2 diabetes mellitus (Cochrane review)
A prescription drug, and the decision sits with a clinician
Acarbose is a prescription medicine. Whether it fits, at what dose, and how fast to build up depends on your blood sugar, your digestion, your other conditions and other medicines. Starting, changing or stopping it belongs with a prescriber, and this page gives no dose because there is no safe general dose to give for a healthy person outside diabetes care.
Gas, bloating and diarrhea are the usual limit
Because acarbose leaves carbohydrate to ferment in the colon, flatulence, bloating, abdominal discomfort and diarrhea are common, especially early and after high-starch meals. These are the main reason people stop the drug. They often ease with a slow dose increase and tend to lessen over weeks, but for many people they are the deciding factor.
Bowel and digestive conditions are a boundary
Acarbose is not appropriate for people with inflammatory bowel disease, significant intestinal obstruction or disorders of digestion and absorption, because a drug that increases fermentation and gas can worsen them. Anyone with a chronic gut condition needs a prescriber to judge whether it is safe at all.
Low blood sugar must be treated with glucose, not table sugar
On its own acarbose rarely causes low blood sugar, but combined with insulin or a sulfonylurea it can. If that happens, the low must be treated with glucose (dextrose), not with ordinary table sugar or fruit, because acarbose slows the breakdown of table sugar into the glucose the body can use quickly. This is a specific safety point a prescriber will explain.
Liver enzymes at higher doses
At higher doses acarbose has been associated with reversible rises in liver enzymes, which is one reason dosing is capped and monitored. This is a matter for the prescriber who sets and reviews the dose, and it resolves when the drug is reduced or stopped.
Not a do-it-yourself longevity drug
There is no completed human trial that establishes a benefit or a dose for acarbose as a way to slow aging. The lifespan evidence is in mice, it is larger in males, and the mechanism that may drive it is the same one that causes its gut side effects. If the longevity question interests you, the appropriate step is a conversation with a knowledgeable clinician who can weigh the trade-offs, not a purchase and a self-made protocol.
Start slow, be smart, read the research, and consult a professional if you have any concerns. This is here to inform your choice, not make it for you.
Common Questions
Does acarbose extend lifespan?
In mice, it does, and the finding is unusually solid: in the National Institute on Aging Interventions Testing Program acarbose extended median lifespan in genetically diverse mice, the effect was much larger in males than females, and it was replicated at higher doses. In people, it has not been shown to extend lifespan or healthspan. No completed human longevity trial exists, so the accurate summary is a striking and replicated animal result with no human confirmation yet.
Why is the effect stronger in male mice?
That sex difference is not fully explained. Across the Interventions Testing Program, acarbose extended male mouse lifespan far more than female, and a later higher-dose study confirmed the pattern. Researchers suspect it involves differences in how males and females handle the drug and its effects on the gut and metabolism, but the mechanism behind the sex gap is not established. It is one more reason the mouse result cannot be read straight across to people of either sex.
Does acarbose protect the heart?
The better evidence says no. The idea comes from the STOP-NIDDM trial, which reported fewer cardiovascular events, but that rested on a small number of events in a secondary analysis and was widely questioned. The ACE trial was designed to test it directly in more than six thousand people with coronary heart disease and prediabetes, and it found no reduction in cardiovascular events, while confirming that acarbose reduced the onset of diabetes.
What are the main side effects?
They are almost all digestive. Flatulence, bloating, abdominal discomfort and diarrhea are common, because the drug leaves carbohydrate to ferment in the colon, and they are the usual reason people stop taking it. They tend to be worst early and after high-starch meals and often ease with a slow dose increase. At higher doses acarbose has also been linked to reversible rises in liver enzymes, which is part of why the dose is capped and monitored.
Explore Related
Other pages this one connects to, by the evidence they share, the outcomes they touch, and the ground they cover.
All 9 sources on this page independently checked and cross-referenced.
Thomas Dehli, Founder & Editor, Sacred Lotus
Sacred Lotus has published Chinese medicine reference material since 2001. Integrative pages are held to the same standard as the herb and formula library: cite the source, grade the claim at its real strength, and say where the research has not looked. This page is educational and it is not medical advice. Last reviewed and updated August 9, 2026.
Evidence strength
How confidently the research supports a claim. Strength describes the evidence, not our endorsement.